HemoSavin Pharma

Clinically Significant Full Correction Blood Loss Reduction in HA Mice by oral administration at 6mg/mouse

Significant Improvement in Clotting Parameters for Hemophilia A (HA), Mouse Dog, Human plasma and ex-vivo Human Blood Studies

Full Correction in Blood Loss¹: 70%
Reduction in Clotting Time (aPTT) in Humans²: 50%
Reduction in Clotting Time (aPTT) in Dogs³: 45%
Decrease in Whole Blood Coagulation Time⁴: 45%

^{1. Tail-clip studies done in oral in-vivo Hemophilia A mouse model} ^{2. In-vivo Hemophilia A human plasma} ^{3. In-vivo Hemophilia A canine plasma} ^{4. Patient side ex-vivo human Hemophilia A blood}

Hemophilia A is a $12.5B/yr Problem Globally (US$59M UAE)

Current solutions are far from perfect and better therapies are needed

$4B/yr in the US and $4B/yr in Japan
Caused by deficiency of Factor VIII, a critical clotting protein
Patients bleed more than normal from injuries or spontaneously in severe cases
Cause of early death! Can reduce life expectancy by 6-10 years

Meet our team

The core and advisory team has expertise across the entire development roadmap

Dr. Mak Gore

President/CTO

Inventor of HemoSavin. Author of 287 global and 61 US patents. 21+ years of experience in high-technology business and intellectual property.
Ashay Gore

Science Officer

Operations experience in biologics manufacturing. Implementation experience in marketing. Project management and entrepreneurship at Innosphere Ventures.
Dr. Steven Pipe

Preclinical Advisor

Chair Professor of Pediatrics and Pathology at The University of Michigan. Medical Director of the Pediatric in Hemophilia and Coagulation Disorders Program and the Special Coagulation Laboratory.
Dr. Suresh Yeola

Preclinical Advisor

20+ years of experience in drug metabolism and pharmacokinetics (DMPK). Completed DMPK studies of INCIVEK^TM and KALYDECO^TM.
Dr. Sarath Kanekal

FDA/Clinical Advisor

25+ years of executive and consultancy experience in biotechnology. Successfully filed 36 FDA Orphan Drug Designation (ODD), Investigational New Drug (IND), and New Drug (NDA) Applications.
Rajeshwari (Raj)

VP Business Development

Contact at email: rajk@yewsavin.com and phone: +1 (541) 231-6658